Weiss Ratings Reiterates Sell (D-) Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Key Points

• Weiss Ratings has reiterated a "sell (D-)" rating for Taysha Gene Therapies (NASDAQ:TSHA), signaling a negative outlook from the firm on the stock's performance.
• Other analysts have varying opinions, with Needham & Company and others rating the stock as "buy" and setting target prices between $8.00 and $12.00, indicating some optimism from different sectors in the market.
• Taysha Gene Therapies reported a loss per share of ($0.09) in its last earnings result, missing expectations, while also showing revenue of $1.99 million for the quarter, exceeding forecasts.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

A number of other equities research analysts also recently commented on TSHA. Needham & Company LLC raised their target price on Taysha Gene Therapies from $8.00 to $10.00 and gave the company a "buy" rating in a report on Thursday, October 2nd. Robert W. Baird upped their price target on Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an "outperform" rating in a report on Thursday, October 2nd. Bank of America assumed coverage on Taysha Gene Therapies in a research note on Friday, July 11th. They set a "buy" rating and a $8.00 target price for the company. Chardan Capital increased their target price on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Finally, Wells Fargo & Company raised their target price on Taysha Gene Therapies from $7.50 to $8.00 and gave the company an "overweight" rating in a research note on Wednesday, August 13th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Taysha Gene Therapies currently has an average rating of "Moderate Buy" and a consensus price target of $9.00.

Taysha Gene Therapies Stock Performance

Shares of TSHA traded up $0.34 during trading hours on Wednesday, hitting $5.06. The stock had a trading volume of 5,839,737 shares, compared to its average volume of 11,303,513. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -14.88 and a beta of 0.99. The firm has a 50-day moving average price of $3.15 and a 200 day moving average price of $2.53. The company has a debt-to-equity ratio of 0.17, a quick ratio of 12.48 and a current ratio of 12.48. Taysha Gene Therapies has a fifty-two week low of $1.05 and a fifty-two week high of $5.40.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). The business had revenue of $1.99 million for the quarter, compared to analysts' expectations of $1.61 million. Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%. As a group, research analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Buying and Selling

In other news, insider Sukumar Nagendran sold 200,000 shares of the company's stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total value of $646,000.00. Following the completion of the transaction, the insider directly owned 1,006,439 shares of the company's stock, valued at $3,250,797.97. This represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 3.78% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TSHA. Millennium Management LLC purchased a new position in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $262,000. Rhumbline Advisers lifted its stake in shares of Taysha Gene Therapies by 7.0% during the 1st quarter. Rhumbline Advisers now owns 205,462 shares of the company's stock valued at $286,000 after buying an additional 13,383 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Taysha Gene Therapies during the 1st quarter valued at $117,000. XTX Topco Ltd purchased a new stake in Taysha Gene Therapies in the 1st quarter worth $282,000. Finally, Jefferies Financial Group Inc. purchased a new stake in Taysha Gene Therapies in the 1st quarter worth $341,000. Institutional investors own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.